Helus Pharma (STU:R7E) Total Current Assets: €159.61 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R7E Helus Pharma Inc STU:R7E
38 GF Score
Price €6.39
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Total Current Assets?

Helus Pharma STU:R7E +2.73% 38 Total Current Assets is €159.61 Mil as of Mar. 2026. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Helus Pharma's total current assets for the quarter that ended in Mar. 2026 was €159.61 Mil.

Helus Pharma  (STU:R7E) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Helus Pharma's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=136.028-16.761+0.75 * 4.349+0.5 * 0
=122.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Total Current Assets Related Terms

Helus Pharma Total Current Assets Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Total Current Assets Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Assets
Get a 7-Day Free Trial 42.44 16.01 148.80 106.79 159.61

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.79 124.55 97.62 190.35 159.61
STU:R7E
38GF Score
Helus Pharma Inc STU:R7E
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Helus Pharma's Total Current Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=136.028+4.349+0+19.235
=159.61

Helus Pharma's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=136.028+4.349+0+19.235
=159.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €159.61 Mil mean?
Helus Pharma (STU:R7E) has a Total Current Assets of €159.61 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Helus Pharma and its competitors.
Is Helus Pharma's Total Current Assets too high?
Helus Pharma's current Total Current Assets is €159.61 Mil. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Total Current Assets compare to VRTX and REGN?
Helus Pharma's Total Current Assets of €159.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Helus Pharma and its competitors. Helus Pharma's current Total Current Assets is €159.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current Total Current Assets of €159.61 Mil. The current Total Current Assets is €159.61 Mil. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current Total Current Assets is €159.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges HELP:USAHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score

Get the complete analysis for STU:R7E

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.39
Price